Stilla Technologies is a Paris-based European biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing biologists with tools for high-resolution genetic analysis.
Stilla Technologies was founded in 2013 and is now part of Bio-Rad Laboratories as LSG-Paris entity.
Since 2016, Stilla Technologies/Bio-Rad LSG-Paris is providing research organizations specialized in molecular biology and genetic analysis. LSG-Paris has developed a range of digital PCR instruments (Naica®, Nio® and now QX700™ systems), which, combined with microfluidic chips, dedicated reagents, and advanced data analysis software, allow the analysis of an unrivalled number of genetic biomarkers (multiplexing) with very high sensitivity and precision. This cutting-edge technology paves the way for new precision genetic tests in a wide range of applications such as liquid biopsy tests for cancer diagnostics, pre-natal testing, Gene Therapy, infectious disease or GMO detection.
Our multi-disciplinary teams in microfluidics, mechanical engineering, biology, and software shares a passion for building successful Life Science Products based on deep technological innovation. We aim to empower scientists with pioneering digital PCR solutions to build the future of genetic testing.